Core Insights - The innovative dual-target weight loss drug, Masitide, developed independently in China, has been published in the prestigious journal Nature, highlighting the global recognition of Chinese original drug research [1][3]. Group 1: Scientific Recognition - Nature magazine is regarded as a benchmark for breakthroughs in basic science and advanced medicine, indicating the international acknowledgment of the scientific value and clinical significance of domestic innovative drugs [3]. - Masitide has been recognized by both Nature and the New England Journal of Medicine, marking a shift for China in the treatment of metabolic diseases from "participating in international competition" to "developing leading capabilities" [5]. Group 2: Clinical Efficacy - Clinical research results show that after 48 weeks of treatment, the average liver fat content in patients decreased by 80.2%, demonstrating significant metabolic improvement [5]. - Masitide is tailored to the physical characteristics of Chinese patients, primarily addressing abdominal obesity and associated metabolic abnormalities by effectively activating the GCG receptor to enhance energy expenditure and reduce visceral fat [3].
国产减重降糖新药凭硬实力登顶《自然》